Literature DB >> 16274845

Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity.

J M Kelly1, A J G Moir, K Carlson, Y Yang, S MacNeil, J W Haycock.   

Abstract

alpha-MSH is an anti-inflammatory peptide which signals by binding to the melanocortin-1 receptor (MC1R) and elevating cyclic AMP in several different cells and tissues. The carboxyl terminal peptides of alpha-MSH (KPV/GKPV) are the smallest minimal sequences that prevent inflammation, but it is not known if they operate via MC1R or cyclic AMP. The aim of this study was to examine the intracellular signaling potential of the GKPV peptide sequence when immobilized to polystyrene beads via a polyethylene glycol moiety. Beads containing an immobilized GKPV peptide were investigated for their ability to inhibit proinflammatory tumor necrosis factor-alpha (TNF-alpha) stimulated activation of NF-kappaB in HBL cells stably transfected with an NF-kappaB-luciferase reporter construct. Peptide functionalized beads were compared with the ability of soluble peptide alone (alpha-MSH or GKPV) or non-functionalized beads to inhibit TNF-alpha stimulated activation of NF-kappaB. GKPV peptide functionalized beads significantly inhibited NF-kappaB-luciferase activity in comparison to beads containing no peptide moiety in one of two growths conditions investigated. Soluble alpha-MSH and GKPV peptides were also confirmed to inhibit NF-kappaB-luciferase. The present study suggests that the carboxyl terminal MSH peptide acts via a cell receptor-based mechanism and furthermore may support the potential use of such immobilized ligands for anti-inflammatory therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274845     DOI: 10.1016/j.peptides.2005.03.062

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 2.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

Review 3.  The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease.

Authors:  Sarah A Ingersoll; Saravanan Ayyadurai; Moiz A Charania; Hamed Laroui; Yutao Yan; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-22       Impact factor: 4.052

4.  PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

Authors:  Guillaume Dalmasso; Laetitia Charrier-Hisamuddin; Hang Thi Thu Nguyen; Yutao Yan; Shanthi Sitaraman; Didier Merlin
Journal:  Gastroenterology       Date:  2007-10-17       Impact factor: 22.682

5.  Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides.

Authors:  Tazeen J Ahmed; Trinidad Montero-Melendez; Mauro Perretti; Costantino Pitzalis
Journal:  Int J Inflam       Date:  2013-05-07

6.  Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.

Authors:  Emilie Viennois; Sarah A Ingersoll; Saravanan Ayyadurai; Yuan Zhao; Lixin Wang; Mingzhen Zhang; Moon Kwon Han; Pallavi Garg; Bo Xiao; Didier Merlin
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.